Bicara Therapeutics Inc (NASDAQ:BCAX) reported a narrower-than-expected loss for the second quarter on Tuesday.

The company posted quarterly losses of 82 cents per share which beat the analyst consensus estimate of losses of 84 cents per share. This represents a 64% decrease over losses of 50 cents per share in the year-ago period.

Bicara Therapeutics shares dipped 14.3% to close at $23.76 on Tuesday.

These analysts made changes to their price targets on Bicara Therapeutics following earnings announcement.

• BTIG analyst Jeet Mukherjee maintained the stock with a Buy and raised the price target from $28 to $39.
• Wells Fargo analyst Eva Fortea Verdejo maintained the stock with an Equal-Weight rating and raised the price target from $16 to $23.

Considering buying BCAX stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.